performed; and between 2010 and 2014, 67 DPB and 282 PTA/S were performed. Of the 514 DPB and 649 PTA/S, 193 and 175 fit our comparison group criteria, respectively. DPB patients were similar in age (70 vs 71 years; P ¼ .48), more often male (72% vs 45%; P < .001), and less often current smokers (12% vs 22%; P ¼ .04). Among DPB patients, the most common inflow artery was the below-knee popliteal (40%), while the most frequently treated PTA/S vessel was the anterior tibial (50%). Surgical site infections occurred in 7% of DPB limbs, and total hospital length of stay was significantly longer after DPB (12 vs 7 days; P < .001). Perioperative complications, including mortality (3% vs 4%; P ¼ .45), did not differ between groups. Kaplan-Meier estimates illustrated that DPB had significantly higher 5-year primary patency (72% vs 52%; P < .01) and freedom from restenosis (53% vs 40%; P ¼ .03), and similar rates of 5-year freedom from reintervention (62% vs 59%; P ¼ .87), limb salvage (78% vs 84%; P ¼ .85), and survival (47% vs 43%; P ¼ .38). Lastly, multivariable analyses demonstrated that DPB significantly protected against restenosis (hazard ratio, 0.6; 95% confidence interval, 0.4-0.9) and improved primary patency (hazard ratio, 0.4; 95% confidence interval, 0.2-0.7).
Objectives: Outpatient use of atherectomy has grown rapidly in recent years, particularly in the physician office setting. Outcomes of this practice are poorly understood. Our study evaluated real world results of atherectomy done for claudication for infrainguinal occlusive disease. We looked at the downstream results of intervention done in the office setting compared to the hospital outpatient setting.
Methods: Analysis of Medicare Part B procedure and claims data summary from 2012 to 2014 using the 5% samples were recorded. The longitudinal analysis assessed upstream utilization 18 months before the incident atherectomy procedure, services rendered during the incident peripheral vascular intervention (PVI), and utilization up to 12 months after the incident PVI. Incident events were identified between January 1, 2012, and June 30, 2013. We used a rolling 12-month downstream time frame to tag other events associated with the beneficiary. Analyses were limited to "incident" procedures of femoral-popliteal atherectomy (Current Procedural Terminology code 37225) or tibial-peroneal atherectomy (code 37229). For each downstream service, we calculated the percentage of unique patients receiving that service.
Results: We analyzed 924 patients undergoing femoral-popliteal atherectomy (262 office-based and 662 hospital outpatient-based). Of these, 40.1% and 31.6% of femoral-popliteal atherectomy patients in the office-based and hospital outpatient-based groups, respectively, had repeat PVI within 1 year of their incident procedure. Need for any lower extremity amputation was 2.7% in the office-based group and 4.8% in the hospital outpatient group. Major amputation was performed in 1.9% and 2.9% of patients, respectively (Table I ). A total of 423 patients undergoing tibial-peroneal atherectomy were analyzed (202 office-based and 221 hospital outpatient-based). Of these, 44.6% and 34.8% of tibialperoneal atherectomy patients in the office-based and hospital outpatient-based groups, respectively, had repeat PVI within 1 year of their incident procedure. Need for any lower extremity amputation was 4.4% and 10.4% in the office-based group and 4.8% in the hospital outpatient group. Major amputation was performed in 3.0% and 7.2% of patients, respectively (Table II) .
Conclusions: We believe this is the first time that Medicare claimsbased utilization data for atherectomy procedures and repeat procedures among patients being treated for claudication have been compared across office-based and hospital outpatient-based cohorts. Considering the high rate of amputation in both hospital outpatient and physician office settings, the data suggest that atherectomy for occlusive disease in the femoral-popliteal and tibial-peroneal segments Objectives: The video demonstrates the anatomical relations and the important steps in the surgical treatment of type 3 popliteal entrapment. This is the second leg treated in this young adult. It concludes with this anomaly shown on magnetic resonance imaging in four of the patient's male relatives.
http://www.conferenceabstracts.com/uploads/cfp2/attachments/ZRFDQ HCR/ZRFDQHCR-285491-1-ANY (1).mp4
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Long-Term Patency of Venous and Synthetic Conduits for Ipsilateral Internal Carotid Artery Bypass
Andre Ramdon, Krishna Martinez-Singh, Jeffrey Hnath, Benjamin Chang, R. Clement Darling III. Albany Medical College, Albany, NY Objectives: Ipsilateral internal carotid artery bypass has been successfully used to treat aneurysms, infection, tumor, and occlusive disease. The purpose of this study was to evaluate the long-term outcomes of autogenous and prosthetic conduits used for ipsilateral internal carotid artery bypass.
Methods: A retrospective review of a single institution registry was performed to identify patients with ipsilateral carotid artery bypass. Demographics, complications, and patency were recorded and compared using c 2 , Fisher exact, and log-rank analysis. Results: From 1994 to 2016, 105 patients underwent ipsilateral carotid artery bypass (86 prosthetic, 19 veins) . The venous bypass group (VBG) and prosthetic bypass group (PBG) were different in terms of gender (8 men and 11 women vs 58 men and 28 women; P ¼.038) but were similar in age (mean VGB: 63 years; range, 18-80; PBG: 68 years; range, 33-88; P ¼ .052). Mean follow-up was 53 months (range, 1 month-15 years). Diabetes, pulmonary disease, hypercholesterolemia, and tobacco use was not statistically significant between groups. Indications were different between groups, with more PBG used for occlusive disease and more VBG used for infection, aneurysm, trauma, and tumor (Fisher exact test P ¼ .004). There were 81 prosthetic bypasses performed for occlusive disease which was 
